Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMRA-101
- Development stage
- Preclinical
- Lead developer
- Damora Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
DMRA-101 is a preclinical biologic candidate, specifically a monoclonal antibody, being developed by Damora Therapeutics for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia and myelofibrosis. The drug is designed to selectively target mutant calreticulin (CALR), a protein that, when mutated, acquires a unique C-terminal tail. This mutant tail constitutively binds to and activates the thrombopoietin receptor (MPL), driving the overproduction of blood cells characteristic of MPNs. By binding to the mutant CALR protein, DMRA-101 aims to block this pathogenic interaction and normalize MPL signaling. Damora Therapeutics is currently advancing DMRA-101 through IND-enabling studies, with an Investigational New Drug (IND) filing anticipated in 2026.
02
Targets
TPOR (Thrombopoietin receptor)CALR mutant (Calreticulin Mutant Protein)
Beyond the preview
Go deeper on DMRA-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMRA-101.